These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24986792)

  • 21. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
    Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
    Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
    Pidala J; Kim J; Anasetti C; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez HF
    J Hematol Oncol; 2010 Oct; 3():36. PubMed ID: 20925957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
    McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.
    Gürlek Gökçebay D; Azik F; Ozbek N; Isik P; Avci Z; Tavil B; Kara A; Tunc B
    Pediatr Transplant; 2015 May; 19(3):307-15. PubMed ID: 25661259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
    Yeh RF; Pawlikowski MA; Blough DK; McDonald GB; O'Donnell PV; Rezvani A; Deeg HJ; McCune JS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):265-72. PubMed ID: 21736869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
    Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
    Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
    Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan.
    Iemura T; Kondo T; Ueda A; Maeda T; Kitawaki T; Arai Y; Kanda J; Ikeda T; Imada K; Ishikawa T; Anzai N; Itoh M; Takeoka T; Akasaka T; Yago K; Yonezawa A; Arima N; Kitano T; Nohgawa M; Watanabe M; Moriguchi T; Yamashita K; Ueda Y; Matsumoto K; Takaori-Kondo A
    Ann Hematol; 2023 Oct; 102(10):2909-2922. PubMed ID: 37052663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
    Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.